These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 37314699)

  • 1. A safety review of current monoclonal antibodies used to treat multiple sclerosis.
    Costa GD; Comi G
    Expert Opin Drug Saf; 2023; 22(11):1011-1024. PubMed ID: 37314699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in preventing adverse events during monoclonal antibody management of multiple sclerosis.
    De Giglio L; Grimaldi AE; Fubelli F; Marinelli F; Pozzilli C
    Expert Rev Neurother; 2019 May; 19(5):417-429. PubMed ID: 31094239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoclonal antibody treatments for multiple sclerosis.
    Rose JW; Foley J; Carlson N
    Curr Neurol Neurosci Rep; 2008 Sep; 8(5):419-26. PubMed ID: 18713579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD20 monoclonal antibodies for the treatment of multiple sclerosis: up-to-date.
    Ancau M; Berthele A; Hemmer B
    Expert Opin Biol Ther; 2019 Aug; 19(8):829-843. PubMed ID: 31027436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Possibilities and risks of the monoclonal antibody alemtuzumab as a new treatment option for multiple sclerosis].
    Warnke C; Kieseier BC; Zettl U; Hartung HP
    Nervenarzt; 2009 Apr; 80(4):468-74. PubMed ID: 19296065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Product review on MAbs (alemtuzumab and ocrelizumab) for the treatment of multiple sclerosis.
    Gabelić T; Barun B; Adamec I; Krbot Skorić M; Habek M
    Hum Vaccin Immunother; 2021 Nov; 17(11):4345-4362. PubMed ID: 34668842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoclonal antibodies in the treatment of multiple sclerosis.
    Di Pauli F; Berger T; Reindl M
    Curr Med Chem; 2009; 16(36):4858-68. PubMed ID: 19929782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A systematic review of the safety and efficacy of monoclonal antibodies for progressive multiple sclerosis.
    Sabahi Z; Daei Sorkhabi A; Sarkesh A; Naseri A; Asghar-Rezaei N; Talebi M
    Int Immunopharmacol; 2023 Jul; 120():110266. PubMed ID: 37209514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monoclonal antibodies in treatment of multiple sclerosis.
    Rommer PS; Dudesek A; Stüve O; Zettl UK
    Clin Exp Immunol; 2014 Mar; 175(3):373-84. PubMed ID: 24001305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Established and novel disease-modifying treatments in multiple sclerosis.
    Cross AH; Naismith RT
    J Intern Med; 2014 Apr; 275(4):350-63. PubMed ID: 24444048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alemtuzumab for multiple sclerosis.
    Riera R; Porfírio GJ; Torloni MR
    Cochrane Database Syst Rev; 2016 Apr; 4(4):CD011203. PubMed ID: 27082500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic Monoclonal Antibodies and Multiple Sclerosis: The Essentials.
    Heliopoulos I; Patousi A
    Med Chem; 2018 Feb; 14(2):144-154. PubMed ID: 28875861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treating multiple sclerosis with monoclonal antibodies: a 2010 update.
    Buttmann M
    Expert Rev Neurother; 2010 May; 10(5):791-809. PubMed ID: 20420497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of an anti-infective screening and monitoring protocol together with infectious disease consultation in preventing infective adverse events in patients treated with anti-CD20/CD52 agents for multiple sclerosis.
    Zappulo E; Buonomo AR; Moccia M; Pinchera B; Villari R; Petracca M; Lanzillo R; Scotto R; Carotenuto A; Viceconte G; Schiano Moriello N; Bruno L; Gentile I; Brescia Morra V
    Mult Scler Relat Disord; 2022 Jul; 63():103814. PubMed ID: 35487032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drugs in clinical development for multiple sclerosis: focusing on anti-CD20 antibodies.
    Gasperini C; Haggiag S; Ruggieri S
    Expert Opin Investig Drugs; 2013 Oct; 22(10):1243-53. PubMed ID: 23855792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal Antibodies in the Treatment of Relapsing Multiple Sclerosis: an Overview with Emphasis on Pregnancy, Vaccination, and Risk Management.
    Krajnc N; Bsteh G; Berger T; Mares J; Hartung HP
    Neurotherapeutics; 2022 Apr; 19(3):753-773. PubMed ID: 35378683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoclonal Antibodies for Multiple Sclerosis: An Update.
    Graf J; Aktas O; Rejdak K; Hartung HP
    BioDrugs; 2019 Feb; 33(1):61-78. PubMed ID: 30604390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specific immune intervention with monoclonal antibodies for the treatment of multiple sclerosis.
    Trebst C; Voss E; Skripuletz T; Stangel M
    Curr Med Chem; 2010; 17(7):640-50. PubMed ID: 20088763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
    Wingerchuk DM; Carter JL
    Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel monoclonal antibodies for therapy of multiple sclerosis.
    Knier B; Hemmer B; Korn T
    Expert Opin Biol Ther; 2014 Apr; 14(4):503-13. PubMed ID: 24579720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.